Related references
Note: Only part of the references are listed.Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study
A. B. Gottlieb et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies
Di Yan et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort
Catalin Codreanu et al.
BIOLOGICALS (2019)
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naive or Switching Patients: A Systematic Review
Hans C. Ebbers et al.
RHEUMATOLOGY AND THERAPY (2019)
Thyroid diseases and skin autoimmunity
Enke Baldini et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2018)
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
Pei-Tzu Lin et al.
SCIENTIFIC REPORTS (2018)
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis
Jacek Karczewski et al.
AUTOIMMUNITY (2016)
Quality Of Life Assessments In Korean Patients With Rheumatoid Arthritis (Ra): An Analysis From The Phase Iii Trial To Evaluate Equivalence Of The Etanercept Biosimilar Hd203 And Enbrel® In Combination With Methotrexate (Mtx) In Patients With Ra; The Hera Study
S.C. Bae et al.
VALUE IN HEALTH (2014)
The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)
Robert Strohal et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2013)
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Rosa Parisi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept
Jerry Bagel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial
Wolfram Sterry et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
A proposed classification of the immunological diseases
Dennis McGonagle et al.
PLOS MEDICINE (2006)
Reporting of noninferiority and equivalence randomized trials - An extension of the CONSORT Statement
G Piaggio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
S Tyring et al.
LANCET (2006)
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Etanercept as monotherapy in patients with psoriasis
CL Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The pros and cons of noninferiority trials
SJ Pocock
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2003)
Share Paper
